The Incretin Pathway and Therapeutic Targets for Diabetes Mellitus

The Incretin Pathway and Therapeutic Targets for Diabetes Mellitus
Please read through the following information and click continue.

ACPE Universal Program Number: 207-000-07-003-H01
Release Date: March 1, 2007
Expiration Date: March 1, 2010


Description
Diabetes mellitus is a widespread disease that can lead to serious health consequences. It is estimated that in 2005, 20.8 million Americans, or 7 percent of the population, had diabetes. Total health care have annually topped $130 billion for diabetes-related illnesses, and diabetes was listed as the sixth leading cause of death in the United States. However, agents such as incretin mimetics and DPP-IV inhibitors offer new avenues by which medicine can attempt to control this disease.

Learning Objectives
Upon successful completion of this activity, the pharmacist should be better able to:

  1. Review the impact of diabetes mellitus.
  2. Review glucose homeostasis.
  3. Review pathophysiology of type 1 and type 2 diabetes mellitus.
  4. Highlight common therapies used to treat diabetes mellitus.
  5. Explain the incretin pathway.
  6. Review current and future drugs involving the incretin pathway.

Target Audience
The target market for this program is pharmacists.

Instructions for Participation
To receive a certificate of completion that indicates your eligibility for continuing education credit, you must:

  • Review the content of the activity.
  • Successfully complete the post-test (70% or higher).
  • You will have two (2) opportunities to successfully complete the activity.

Your statement of credit will be issued immediately upon successful completion of the post-test and submission of the evaluation.

Fee
There is no fee for this activity.

Accreditation

Pharmacists
ACPE logoNCPA is approved by the Accreditation Council for Pharmacy Education as a provider of continuing pharmacy education. This program will provide 2.0 contact hours (.2 CEUs) of continuing pharmacy education credit under the number 207-000-07-003-H01.

 

Faculty
Kerri DeNucci, PharmD, is a clinical pharmacist at Cabell Huntington Hospital in Huntington, West Virginia.

Disclosure Declaration
It is the policy of the National Community Pharmacists Association (NCPA) to ensure independence, balance, objectivity, scientific rigor, and integrity in all of their continuing education activities.

The author, sponsor, and publisher of this continuing education activity have made all reasonable efforts to ensure that information contained herein is accurate in accordance with the latest available scientific knowledge at the time of accreditation of this continuing education program. Information regarding drugs (e.g., their administration, dosages, contraindications, adverse reactions, interactions, special warnings, precautions) and drug delivery systems are subject to change, however, and the reader is advised to check the manufacturer's package insert for information concerning recommended dosage and potential problems or cautions prior to dispensing or administering the drug or using the drug delivery systems.

Approval of credit for this continuing education activity does not imply endorsement by NCPA of any product or manufacturer identified.

Any medications or treatment methods suggested in this CE activity should not be used by the practitioner without evaluation of their patient's condition(s) and possible contraindication(s) or danger(s) of use of any specific medication.


Software Requirements

PC
Windows 2000
Internet Explorer 5.5 or Firefox
*Adobe Acrobat Reader

MAC
Mac OS 10.2.8
Safari
*Adobe Acrobat Reader

*REQUIRED TO VIEW PRINTABLE VERSION OF CE LESSON

 

 

 

 

Continue